Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study

BACKGROUND: The first large serosurvey in Iran found a SARS-CoV-2 antibody seroprevalence of 17.1% among the general population in the first wave of the epidemic by April, 2020. The purpose of the current study was to assess the seroprevalence of COVID-19 infection among Iranian general population a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamani, Mohammad, Poustchi, Hossein, Mohammadi, Zahra, Dalvand, Sahar, Sharafkhah, Maryam, Motevalian, Seyed Abbas, Eslami, Saeid, Emami, Amir, Somi, Mohammad Hossein, Yazdani-Charati, Jamshid, Saki, Nader, Karami, Manoochehr, Najafi, Farid, Mohebbi, Iraj, Veisi, Nasrollah, Hormati, Ahmad, Pourfarzi, Farhad, Ghadimi, Reza, Ansari-Moghaddam, Alireza, Sharifi, Hamid, Roshandel, Gholamreza, Mansour-Ghanaei, Fariborz, Joukar, Farahnaz, Shayanrad, Amaneh, Eghtesad, Sareh, Niavarani, Ahmadreza, Delavari, Alireza, Kaveh, Soudeh, Feizesani, Akbar, Markarian, Melineh, Shafighian, Fatemeh, Sadjadi, Alireza, Darvishian, Maryam, Malekzadeh, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125542/
https://www.ncbi.nlm.nih.gov/pubmed/35606743
http://dx.doi.org/10.1186/s12889-022-13464-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125542/
https://www.ncbi.nlm.nih.gov/pubmed/35606743
http://dx.doi.org/10.1186/s12889-022-13464-7

Ejemplares similares